TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare. Sex differences in TAVR one-year mortality.

Anticoagulants after TAVR: 5-year survival data favor DOACs over VKAs

However, that one finding does not tell the whole story. Researchers also found that DOACs may increase a TAVR patient's risk of a disabling stroke.

February 15, 2024
AI cardiology heart artificial intelligence deep learning

AI could be a game-changer for TAVR, but cardiologists remain ‘irreplaceable’

The rise of TAVR as a go-to treatment option for many AS patients has been one of the biggest stories in cardiology for several years now. How will advanced AI models impact this trend going forward? 

February 12, 2024
doctor examines patient data on their tablet

TAVR vs. SAVR after 10 years: Similar safety risks, but researchers uncover several key differences

TAVR continues to gain momentum as a go-to treatment option for severe AS, making it more important than ever to investigate long-term outcomes. This latest analysis, published in European Heart Journal, focused on 280 patients randomized to undergo either transcatheter or surgical aortic valve replacement.

February 7, 2024
According to the U.S. government, Asante Health System and one of its surgeons knowingly submitted false claims to Medicare, Medicaid and TRICARE for more than six years. Heart surgery surgeons.

SAVR in the TAVR era: Volumes are down, but it remains the go-to choice for certain patient populations

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

January 30, 2024
ACC 2023 ACC.23 American College of Cardiology

American College of Cardiology announces late-breaking research for ACC.24 in Atlanta

The group's annual meeting heads to Atlanta this April. TAVR, GLP-1 agonists, medical imaging guidance and blood pressure control are just some of the topics that will be presented during late-breaking sessions.

January 29, 2024

Heart surgeons alarmed by high number of young patients choosing TAVR over SAVR

Nearly 50% of patients under the age of 60 are now opting for TAVR over SAVR, according to a new study presented at STS 2024 in San Antonio. "We owe it to our patients to take a more prominent role in providing the highest quality evidence to help our patients make these major healthcare decisions," one researcher said. 

January 28, 2024
Overview of the Tootsie Roll technique for treating paravalvular leak in certain transcatheter heart valve patients. Tootsie Roll paravalvular leak transcatheter heart valves.

New ‘Tootsie Roll’ technique could help cardiologists treat PVL in transcatheter heart valves

Paravalvular leak remains a significant problem after TAVR, SAVR and even TMVR. Could a new-look interventional technique help heart teams overcome this issue and improve patient outcomes? 

January 24, 2024
Pi-Cardia ShortCut TAVR device. According to Pi-Cardia, ShortCut is the first medical device of its kind; interventional cardiologists use it to split valve leaflets in patients who have been recommended for valve-in-valve TAVR and face a heightened coronary obstruction risk.

FDA grants new valve-in-valve TAVR offering its breakthrough device designation

The new device was designed to help clinicians perform valve-in-valve TAVR on certain high-risk patients. One cardiologist familiar with the technology said it could be easily added to any preexisting TAVR workflow. 

January 23, 2024

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup